HK1199212A1 - Method for inhibiting cellular activation by insulin-like growth factor-1 -1 - Google Patents

Method for inhibiting cellular activation by insulin-like growth factor-1 -1

Info

Publication number
HK1199212A1
HK1199212A1 HK14112792.9A HK14112792A HK1199212A1 HK 1199212 A1 HK1199212 A1 HK 1199212A1 HK 14112792 A HK14112792 A HK 14112792A HK 1199212 A1 HK1199212 A1 HK 1199212A1
Authority
HK
Hong Kong
Prior art keywords
insulin
growth factor
cellular activation
inhibiting cellular
inhibiting
Prior art date
Application number
HK14112792.9A
Other languages
English (en)
Chinese (zh)
Inventor
David R Clemmons
Laura A Maile
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Publication of HK1199212A1 publication Critical patent/HK1199212A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK14112792.9A 2011-08-26 2014-12-22 Method for inhibiting cellular activation by insulin-like growth factor-1 -1 HK1199212A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/219,276 US8613922B2 (en) 2003-04-24 2011-08-26 Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
PCT/US2012/052384 WO2013032948A1 (en) 2011-08-26 2012-08-24 Method for inhibiting cellular activation by insulin-like growth factor-1

Publications (1)

Publication Number Publication Date
HK1199212A1 true HK1199212A1 (en) 2015-06-26

Family

ID=47756771

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112792.9A HK1199212A1 (en) 2011-08-26 2014-12-22 Method for inhibiting cellular activation by insulin-like growth factor-1 -1

Country Status (15)

Country Link
US (4) US8613922B2 (es)
EP (1) EP2747784A4 (es)
JP (1) JP6277127B2 (es)
KR (1) KR20140090975A (es)
CN (1) CN104053452B (es)
AU (1) AU2012300314A1 (es)
BR (1) BR112014004385A2 (es)
CA (1) CA2846248A1 (es)
CL (1) CL2014000449A1 (es)
HK (1) HK1199212A1 (es)
IL (1) IL231162A0 (es)
MX (1) MX2014002296A (es)
RU (1) RU2014111472A (es)
WO (1) WO2013032948A1 (es)
ZA (1) ZA201401450B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2015041987A1 (en) * 2013-09-18 2015-03-26 The Board Of Trustees Of The Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
US10822411B2 (en) * 2014-09-15 2020-11-03 The Board Of Trustees Of The Leland Stanford Junior University Targeting aneurysm disease by modulating phagocytosis pathways
EP3261671B1 (en) * 2015-02-27 2020-10-21 The Board of Trustees of the Leland Stanford Junior University Combination therapy for treatment of atherosclerosis
RS62151B1 (sr) 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
EP3397271B1 (en) * 2015-12-30 2021-11-03 Marshall University Research Corporation Compositions and methods for treating retinopathy
PE20181921A1 (es) * 2016-04-14 2018-12-11 Ose Immunotherapeutics NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
IL262251B2 (en) * 2016-04-14 2023-09-01 Ose Immunotherapeutics New anti-syrap antibodies and their medical applications
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
WO2019073080A1 (en) 2017-10-13 2019-04-18 Ose Immunotherapeutics ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
KR20200091901A (ko) 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
BR112020017709A2 (pt) 2018-03-13 2020-12-29 Ose Immunotherapeutics Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos
JP7393342B2 (ja) 2018-03-21 2023-12-06 エーエルエックス オンコロジー インコーポレイテッド シグナル調節タンパク質αに対する抗体及び使用方法
MX2020013068A (es) * 2018-07-10 2021-03-02 Univ Kobe Nat Univ Corp Anticuerpo anti proteína reguladora de señales alfa sirpalfana.
WO2020016655A2 (en) * 2018-07-17 2020-01-23 Helixmith Co., Ltd. Treatment of neuropathy with dna constructs expressing igf-1 isoforms
CA3141130A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
RS65480B1 (sr) 2019-09-18 2024-05-31 Lamkap Bio Alpha AG Bispecifična antitela protiv ceacam5 i cd3
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
MX2023014389A (es) 2021-06-04 2024-03-04 Boehringer Ingelheim Int Anticuerpos anti-sirp-alfa.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5432611A (en) 1977-08-16 1979-03-10 Nobuhiko Katsunuma Glucocorticoid saving factor
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859765A (en) 1983-10-17 1989-08-22 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) 1985-03-01 1989-09-05 Board Of Regents, The University Of Texas System Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4853871A (en) 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5874231A (en) 1994-08-22 1999-02-23 Mcgill University Methods of screening for non-hormone compounds which effect modulation of polypeptide translation
WO1997032601A1 (fr) 1996-03-06 1997-09-12 Chugai Seiyaku Kabushiki Kaisha Procede de criblage de substances induisant l'apoptose
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
HUP0003513A3 (en) 1997-09-11 2004-05-28 Chugai Pharmaceutical Co Ltd Monoclonal antibody inducing apoptosis
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
US6753146B1 (en) 1999-02-23 2004-06-22 Eric F. Bernstein System and method for evaluating agents which prevent oxidative damage
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
WO2002092784A2 (en) 2001-05-15 2002-11-21 Emory University POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47
US7261892B2 (en) * 2001-11-27 2007-08-28 Celltech R&D Limited Methods for diagnosis and treatment of epithelial-derived cancers
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20040213792A1 (en) * 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
EP1693385A4 (en) 2003-11-11 2009-11-04 Chugai Pharmaceutical Co Ltd ANTI-CD47 ANTIBODIES HUMANIZED
EP2629478B1 (en) 2012-02-16 2018-05-16 BlackBerry Limited Method and apparatus for separation of connection data by perimeter type

Also Published As

Publication number Publication date
US20160297866A1 (en) 2016-10-13
WO2013032948A1 (en) 2013-03-07
JP6277127B2 (ja) 2018-02-07
NZ621515A (en) 2016-03-31
CA2846248A1 (en) 2013-03-07
KR20140090975A (ko) 2014-07-18
EP2747784A4 (en) 2015-05-06
US20170114134A1 (en) 2017-04-27
US20140141002A1 (en) 2014-05-22
CN104053452A (zh) 2014-09-17
ZA201401450B (en) 2014-11-26
BR112014004385A2 (pt) 2020-10-27
AU2012300314A1 (en) 2014-03-13
RU2014111472A (ru) 2015-11-27
CL2014000449A1 (es) 2015-01-16
EP2747784A1 (en) 2014-07-02
US9475882B2 (en) 2016-10-25
JP2014525940A (ja) 2014-10-02
IL231162A0 (en) 2014-04-30
US20120039896A1 (en) 2012-02-16
US8613922B2 (en) 2013-12-24
MX2014002296A (es) 2014-03-27
CN104053452B (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
HK1199212A1 (en) Method for inhibiting cellular activation by insulin-like growth factor-1 -1
HRP20181818T1 (hr) Postupak za proizvodnju supstituiranih 5-fluoro-1h-pirazolopiridina
EP2786441A4 (en) METHOD FOR ALKALIATING ANODES
PL2685961T3 (pl) Sposób leczenia urazu neurologicznego
TWI563280B (en) Positioning method
IL229001A0 (en) A method for restraining mosquitoes
PL2732572T3 (pl) Sposób adaptacji rangi łącza w górę
HK1201743A1 (en) Method for improving executive function
ZA201208219B (en) Method for treating wasterwater
EP2650276A4 (en) PROCESS FOR PRODUCTION OF -FLUOROALCOOL
ZA201307067B (en) Method for promoting plant growth
ZA201307066B (en) Method for promoting plant growth
EP2735569A4 (en) PROCESS FOR PREPARING A LANTHIONINE DERIVATIVE
PL2760276T3 (pl) Sposób hodowli roślin
ZA201305985B (en) Method for promoting plant growth
EP2671865A4 (en) METHOD OF MANUFACTURING AN AMINO BINDING
EP2743258A4 (en) PROCESS FOR PURIFYING LEVO-OXIRACETAM
PL2476684T3 (pl) Sposób wytwarzania alkilofosforanów
HK1191327A1 (en) Azaspirodecanone compounds as hsl inhibitors hsl
EP2609190A4 (en) ANTIMICROBIAL PROCESS FOR FERMENTATION PROCESS
IL228744A0 (en) A method for treating diseases related to interferon alpha
EP2752402A4 (en) METHOD OF PREPARING A 2-ALKENYLAMINE COMPOUND
EP2716631A4 (en) METHOD FOR PRODUCING A PROLINK CONNECTION
PL2476685T3 (pl) Sposób wytwarzania alkilofosforanów
EP2674421A4 (en) PROCESS FOR THE PREPARATION OF 2-FURALDEHYDE